Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flunitrazepam is a potent benzodiazepine derivative with strong hypnotic and sedative effects. It acts as a central nervous system (CNS) depressant and is used for the short-term treatment of severe insomnia and as a premedication for anesthesia in countries where it is approved. Its mechanism of action involves enhancing the effect of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter at GABA-A receptors in the brain. This results in sedation (drowsiness), muscle relaxation (skeletal muscle relaxant properties), anxiolysis (reduction of anxiety), and amnesia (memory loss). The drug has a long half-life due to active metabolites. It was patented in 1962 and came into medical use in 1974.[4][6] Flunitrazepam is not approved for medical use in the United States but is available elsewhere under various brand names such as Rohypnol. It has gained notoriety as a "date rape" drug due to its ability to cause anterograde amnesia when administered surreptitiously.[1][3]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on flunitrazepam.